© 2004 by BMJ Publishing Group & British Cardiac Society
Managing the cost of cardiovascular prevention in primary care
Correspondence to:
Correspondence to:
Mr Norman Evans
Wandsworth Primary Care Trust Headquarters, 2nd Floor, Teak Tower, Main Building, Springfield University Hospital, 61 Glenburnie Road, London SW17 7DJ, UK; norman.evans{at}swlondon.nhs.uk
Prescribing costs for the prevention of cardiovascular disease are rising nationally, particularly in relation to implementation of the National Service Framework for coronary heart disease. Prescribing effective treatment that is going to benefit the patients overall managementevidence based medicineis the key to funding drugs for cardiovascular prevention. It is clear that there is a lot of waste within the system. If the current waste in prescribing can be reduced, it should be possible to fund new developments, not only in cardiovascular disease but also in other therapeutic areas.
Keywords: primary care; National Service Framework; coronary heart disease; costs
Abbreviations: ACE, angiotensin converting enzyme; ALLHAT, antihypertensive and lipid lowering treatment to prevent heart attack trial; CHD, coronary heart disease; GMS, General Medical Service; NSF, National Service Framework; PCT, primary care trust
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
